Abstract

KIF20A (RAB6KIFL) belongs to the kinesin superfamilyof motor proteins, which play critical roles in the traffickingof molecules and organelles during the growth of pancreatic cancer.Immunotherapy using a previously identified epitope peptide forKIF20A is expected to improve clinical outcomes. A phase I clinicaltrial combining KIF20A-derived peptide with gemcitabine (GEM) was therefore conducted among patients with advancedpancreatic cancer who had received prior therapy such as chemotherapyand/or radiotherapy. Despite, huge importance of the field, no dedicated AVP resource is available. In the present Research Scientific Project , we have collected 1245 peptides with antiviral activity targeting important human viruses like influenza, HIV, HCV and SARS, etc. After removing redundant peptides, 1056 peptides were divided into 951 training and 105 validation data sets. We have exploited various peptides sequence features, i.e. motifs and alignment followed by amino acid composition and physicochemical properties during 5-fold cross validation using Support Vector Machine. Physiochemical properties-based model achieved maximum 85% accuracy and 0.70 Matthew’s Correlation Coefficient (MCC). Therefore, AVPpred—the first web server for predicting the highly effective AVPs would certainly be helpful to researchers working on peptide-based antiviral development. The web server is freely available at http://crdd.osdd.net/ servers/avpp. Here, in Biogenea we have discovered for the first time an in silico KIF20A-derived Peptide mimic designed poly-chemo-pharmacophoric macroscaffold as a future super-antagonist for the treatment of PatientsWith Advanced Pancreatic Cancer.